Trials / Completed
CompletedNCT00162045
A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects
A Phase I-II, Open-Label, Multicenter Trial to Determine the Dosimetry and Safety of Technetium Tc99m Sestamibi in Pediatric Subjects
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Lantheus Medical Imaging · Industry
- Sex
- All
- Age
- 4 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Technetium Tc99m Sestamibi | Rest and/or stress SPECT imaging study |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2007-05-01
- Completion
- 2007-06-01
- First posted
- 2005-09-13
- Last updated
- 2011-06-02
Locations
10 sites across 3 countries: United States, Canada, Taiwan
Source: ClinicalTrials.gov record NCT00162045. Inclusion in this directory is not an endorsement.